114 related articles for article (PubMed ID: 26526637)
21. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.
Gao Y; Wang J; Zhou Y; Sheng S; Qian SY; Huo X
Sci Rep; 2018 Feb; 8(1):2732. PubMed ID: 29426902
[TBL] [Abstract][Full Text] [Related]
22. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer.
Kochi M; Fujii M; Kanamori N; Kaiga T; Kawakami T; Aizaki K; Kasahara M; Mochizuki F; Kasakura Y; Yamagata M
Gastric Cancer; 2000 Dec; 3(4):177-186. PubMed ID: 11984734
[TBL] [Abstract][Full Text] [Related]
24. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
25. Plasma YKL-40 levels in healthy subjects from the general population.
Bojesen SE; Johansen JS; Nordestgaard BG
Clin Chim Acta; 2011 Apr; 412(9-10):709-12. PubMed ID: 21272568
[TBL] [Abstract][Full Text] [Related]
26. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
Ng WW; Tong KJ; Tam TN; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
[TBL] [Abstract][Full Text] [Related]
27. Serum sAPRIL: a potential tumor-associated biomarker to colorectal cancer.
Ding W; Wang J; Wang F; Wang G; Wu Q; Ju S; Cong H; Wang H
Clin Biochem; 2013 Oct; 46(15):1590-4. PubMed ID: 23792260
[TBL] [Abstract][Full Text] [Related]
28. A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1.
Nielsen HJ; Christensen IJ; Brünner N
Scand J Gastroenterol; 2010; 45(2):200-7. PubMed ID: 20095885
[TBL] [Abstract][Full Text] [Related]
29. Prognostic values of serum CA19-9 and CEA levels for colorectal cancer.
Nakayama T; Watanabe M; Teramoto T; Kitajima M
Oncol Rep; 1997; 4(4):819-22. PubMed ID: 21590148
[TBL] [Abstract][Full Text] [Related]
30. Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer.
Chen C; Chen Q; Zhao Q; Liu M; Guo J
Ann Clin Lab Sci; 2017 May; 47(3):260-263. PubMed ID: 28667025
[TBL] [Abstract][Full Text] [Related]
31. Serum GROβ: a potential tumor-associated biomarker for colorectal cancer.
Zheng Z; Zheng M; Bi J; Feng Q; Yue Z; Zhou Y; Hu W; Zhang H; Gao H
Int J Clin Exp Med; 2015; 8(2):2526-35. PubMed ID: 25932198
[TBL] [Abstract][Full Text] [Related]
32. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
[TBL] [Abstract][Full Text] [Related]
33. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
Grotowski M; Maruszyński M; Piechota W
Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
[TBL] [Abstract][Full Text] [Related]
34. Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients.
Ohuchi N; Takahashi K; Matoba N; Sato T; Taira Y; Sakai N; Masuda M; Mori S
Jpn J Clin Oncol; 1989 Sep; 19(3):242-8. PubMed ID: 2810823
[TBL] [Abstract][Full Text] [Related]
35. Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients.
Nakayama T; Watanabe M; Teramoto T; Kitajima M
Anticancer Res; 1997; 17(2B):1379-82. PubMed ID: 9137502
[TBL] [Abstract][Full Text] [Related]
36. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
37. Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer.
Vocka M; Langer D; Petrtyl J; Vockova P; Hanus T; Kalousova M; Zima T; Petruzelka L
Neoplasma; 2015; 62(3):470-7. PubMed ID: 25866228
[TBL] [Abstract][Full Text] [Related]
38. Genetic correction improves prediction efficiency of serum tumor biomarkers on digestive cancer risk in the elderly Chinese cohort study.
Wang K; Bai Y; Chen S; Huang J; Yuan J; Chen W; Yao P; Miao X; Wang Y; Liang Y; Zhang X; He M; Yang H; Wei Q; Guo H; Wei S
Oncotarget; 2018 Jan; 9(7):7389-7397. PubMed ID: 29484118
[TBL] [Abstract][Full Text] [Related]
39. Carcinoembryonic antigen and carbohydrate antigen 19-9 levels of peripheral and draining venous blood in colorectal cancer patients. Correlation with histopathologic and immunohistochemical variables.
Tabuchi Y; Deguchi H; Saitoh Y
Cancer; 1988 Oct; 62(8):1605-13. PubMed ID: 3167774
[TBL] [Abstract][Full Text] [Related]
40. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
